- Trastuzumab
-
- $0.00 / 1G
-
2023-01-11
- CAS:180288-69-1
- Min. Order: 1G
- Purity: 98%min
- Supply Ability: 30kg/month
- Trastuzumab
-
- $1.00 / 1g
-
2021-07-20
- CAS:180288-69-1
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
- Trastuzumab USP/EP/BP
-
- $1.10 / 1g
-
2021-07-03
- CAS:180288-69-1
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Trastuzumab Basic information |
| Product Name: | Trastuzumab | | Synonyms: | TrastuzuMab(Herceptin);TRASTUZUMAB 98 % +;IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer;TRASTUZUMAB 95 % +;Anti HER2, Ig gamma-1 chain C region;Recombinant humanized anti-HER2 antibody;RhuMab HER2;Trastuzumab - 20mg/ml in PBS | | CAS: | 180288-69-1 | | MF: | C10H14N6O5 | | MW: | 298.25536 | | EINECS: | | | Product Categories: | | | Mol File: | 180288-69-1.mol |  |
| | Trastuzumab Chemical Properties |
| storage temp. | Store at -20°C |
| | Trastuzumab Usage And Synthesis |
| Uses | Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protien. As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu positive cancer. | | Indications | The introduction of herceptin (Trastuzumab) into clinical
practice for the treatment of breast cancer marks a
major advance in the use of monoclonal antibody cancer
therapy. Herceptin is a humanized antibody directed
against the HER-2 antigen that is overexpressed
on the tumor cell surface in approximately 25% of
breast cancer patients. HER-2/neu/erbB2 overexpression
marks an aggressive estrogen receptor–negative
form of breast cancer. Therefore, a therapeutic agent
selective for this target is particularly valuable.
Herceptin is administered by intravenous infusion and
in conjunction with paclitaxel can extend survival in
patients with HER-2/neu/erbB2 overexpressing metastatic
breast cancer.Herceptin use is associated with infusion-
related hypotension, flushing and bronchoconstriction,
and skin rash but no bone marrow toxicity.
Herceptin appears to sensitize patients to cardiotoxicity,
an important concern in patients also receiving
doxorubicin. | | Definition |
Herceptin (generic name: trastuzumab) is not a chemo drug, it is a targeted therapy anticancer drug.
Herceptin contains one active ingredient, trastuzumab, and is given as an intravenous (IV) infusion slowly into a vein. Herceptin Hylecta contains two active ingredients, trastuzumab and hyaluronidase-oysk, and is given as a subcutaneous injection, which is an injection that goes under the skin.
| | Mechanism of action | Trastuzumab is a monoclonal antibody against human epidermal growth factor receptor 2 (HER2). Trastuzumab binds to an extracellular domain of this receptor and inhibits HER2 homodimerization, thereby preventing HER2-mediated signaling. It is also thought to facilitate antibody-dependent cellular cytotoxicity, leading to the death of cells that express HER2. Its mechanism differs slightly from that of the newer agent pertuzumab; the latter inhibits hetero-dimerization of HER2 with HER3, a related growth factor receptor. Trastuzumab has been shown to bind three distinct regions of domain IV of the HER2 extracellular domain through electrostatic and hydrophobic bindings[1].
| | References | [1] Hamid Maadi. “Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.” Cancers (2021).
|
| | Trastuzumab Preparation Products And Raw materials |
|